Kymera Therapeutics, Inc. (KYMR) Financial Statements (2024 and earlier)

Company Profile

Business Address 200 ARSENAL YARDS BLVD., SUITE 230
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments407,166442,418296,202
Cash and cash equivalents68,39547,97631,004
Short-term investments338,771394,442265,198
Receivables   577
Contract with customer, asset, after allowance for credit loss2,537135856
Deferred costs   400
Other undisclosed current assets9,7138,7204,304
Total current assets:419,416451,273302,339
Noncurrent Assets
Operating lease, right-of-use asset8,9099,4269,845
Property, plant and equipment13,33411,88110,841
Long-term investments and receivables152,328125,187162,531
Long-term investments152,328125,187162,531
Restricted cash and investments6,1306,1161,589
Other noncurrent assets3,0172,02230
Total noncurrent assets:183,718154,632184,836
TOTAL ASSETS:603,134605,905487,175
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities31,83726,97614,698
Accounts payable4,3354,0054,368
Accrued liabilities27,50222,97110,330
Deferred revenue35,26061,73992,552
Debt1,4081,138689
Other liabilities303228106
Other undisclosed current liabilities2,5352,4612,572
Total current liabilities:71,34392,542110,617
Noncurrent Liabilities
Long-term debt and lease obligation1,24614,36414,732
Finance lease, liability1,2461,140604
Liabilities, other than long-term debt40,39439,36177,938
Deferred revenue28,00039,29577,838
Other liabilities24866100
Operating lease, liability12,14613,22414,128
Total noncurrent liabilities:41,64053,72592,670
Total liabilities:112,983146,267203,287
Equity
Equity, attributable to parent490,151459,638283,888
Common stock654
Additional paid in capital878,884689,275412,777
Accumulated other comprehensive loss(4,949)(660)(128)
Accumulated deficit(383,790)(228,982)(128,765)
Total equity:490,151459,638283,888
TOTAL LIABILITIES AND EQUITY:603,134605,905487,175

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Revenues46,82672,83234,034
Gross profit:46,82672,83234,034
Operating expenses(208,082)(173,362)(80,338)
Operating loss:(161,256)(100,530)(46,304)
Nonoperating income
(Other Nonoperating income)
6,448313711
Interest and debt expense(179)(158)(121)
Loss from continuing operations:(154,987)(100,375)(45,714)
Loss before gain (loss) on sale of properties:(100,375)(45,714)
Other undisclosed net income179158121
Net loss:(154,808)(100,217)(45,593)
Other undisclosed net income attributable to parent   
Net loss attributable to parent:(154,808)(100,217)(45,593)
Preferred stock dividends and other adjustments   (9,050)
Net loss available to common stockholders, diluted:(154,808)(100,217)(54,643)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Net loss:(154,808)(100,217)(45,593)
Comprehensive loss:(154,808)(100,217)(45,593)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(4,289)(532)(134)
Comprehensive loss, net of tax, attributable to parent:(159,097)(100,749)(45,727)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: